Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Oramed Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ORMD-0801 (oral insulin) capsule, with enhanced patient compliance, is currently undergoing phase III clinical trials for the T2DM indication. Drug has the potential to delay the disease progression or even eliminating late-stage complications.
Brand Name : ORMD-0801
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Oramed Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
